Acurx Pharmaceuticals, Inc. (ACXP) |
|
3.63 -0.17 (-4.47%)
|
06-29 18:10 |
|
Open: |
3.85 |
Pre. Close: |
3.8 |
|
High:
|
3.91 |
Low:
|
3.62 |
|
Volume:
|
30,568 |
Market Cap:
|
37(M) |
|
|
|
|
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.91 - 3.93 |
3.93 - 3.95 |
|
Low:
|
3.58 - 3.6 |
3.6 - 3.61 |
|
Close:
|
3.6 - 3.63 |
3.63 - 3.66 |
|
Technical analysis |
as of: 2022-06-29 4:51:12 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 4.67 One year: 5.45 |
| Support: |
Support1: 2.98 Support2: 2.35 |
| Resistance: |
Resistance1: 4 Resistance2: 4.67 |
| Pivot: |
3.65  |
| Moving Average: |
MA(5): 3.67 MA(20): 3.4
MA(100): 3.5 MA(250): 4.28 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 77.1 %D(3): 77.5 |
| RSI: |
RSI(14): 58.9 |
| 52-week: |
High: 6.34 Low: 2.32 |
| Average Vol(K): |
3-Month: 16 (K) 10-Days: 9 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACXP ] has closed above bottom band by 46.6%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 29 Jun 2022
Stock Alert: Acurx (ACXP) Down 7.90% in Pre-Market Move for June 29 - Equities News
Wed, 22 Jun 2022
Acurx Pharmaceuticals (NASDAQ:ACXP) Stock Price Down 0.3% - Defense World
Thu, 17 Mar 2022
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update - PR Newswire
Wed, 23 Feb 2022
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) Announce Publication of Ibezapolstat Phase 2a Clinical Study Results In Clinical Infectious Disease - BP Journal
Mon, 31 Jan 2022
Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist | BioPub - Midas Letter
Thu, 30 Sep 2021
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
10 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
23.3 (%) |
|
% Held by Institutions
|
3.1 (%) |
|
Shares Short
|
49 (K) |
|
Shares Short P.Month
|
87 (K) |
Stock Financials |
|
EPS
|
-1.49 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.03 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-122.5 |
|
Return on Equity (ttm)
|
-211.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-6 (M) |
|
Levered Free Cash Flow
|
-2 (M) |
Stock Valuations |
|
PE Ratio
|
-2.45 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.49 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.88 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
